USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Carigent Therapeutics
Address:
5 Science Park
Suite 13
New Haven, CT 06511 1966
Phone:
(203) 752-0808
URL:
N/A
EIN:
208056399
DUNS:
605510093
Number of Employees:
5
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
Yes

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $454,802.00 3

Award List:

Long Circulating Targeted Nanoparticles for non-Hodgkin's Lymphoma Treatment

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$153,437.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objectives of this proposal Long-Circulating Targeted Nanoparticles for Non-Hodgkin's Lymphoma Treatment are to (1) develop a novel, surface-modified PLGA nanoparticle system for the targeted delivery of therapeutic compounds and (2) use this… More

Multimodal Diagnostic and Therapeutic Nanoparticles for Non-Hodgkin's Lymphoma

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$204,344.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term clinical objective of this proposal Multimodal Diagnostic and Therapeutic Nanoparticles for Non-Hodgkin's Lymphoma is the development of a novel therapeutic and diagnostic drug delivery technology for sp ecific use in the treatment of… More

SBIR PHASE I: Tumor-Targeting Particles for the Delivery of Paclitaxel Against Ovarian Cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$97,021.00
Agency:
NSF
Principal Investigator:
Abstract:
PARS Summary This Small Business Innovation Research (SBIR) Phase I research project aims to develop paclitaxel-loaded nano particles with avidin modified surfaces for the targeting of the drug to cells that express an appropriate receptor for which the particle also carries the ligand. … More